|
With a strategy similar to HVP III, Hatteras Venture Partners IV (HVP IV) was launched in August 2011 with a first close of $74 million toward a final fund target of $125 million. With HVP IV, Hatteras has formally launched "Hatteras Discovery", an allocation of the fund focused on seed-stage companies and projects in the field of human medicine and life sciences.
www.clearsidebio.com
Clearside Biomedical is an ophthalmic company specializing in the research, development and commercialization of therapeutic products through a proprietary ocular microinjection platform that targets the individual compartments of the eye. Currently, Clearside Biomedical is focused on its initial product candidate, CLS1001, under development for retinal applications through the delivery of proven therapeutics to the suprachoroidal space. Clearside Biomedical was founded by an executive team with extensive development and revenue growth expertise, focused on improving the delivery of therapeutic agents to improve standard of care for patients with sight threatening disease.
www.deviceinnovationgroup.com
Device Innovation Group ("DIG") was founded in 2011 as the result of a partnership between medical device company MDI Partners and two venture capital firms, TriStar Technology Fund and Limestone Fund. The company’s mission is to develop early stage medical devices that fulfill unmet clinical needs and underserved markets that are often overlooked by larger investment firms. DIG will incorporate a “fail fast” philosophy and a strategy of rapid advancement, welcoming new innovation from various sources including universities, hospitals and entrepreneurs.
Hatteras Venture Partners III (HVP III) is an $83 million venture capital fund focused on seed and early stage investments in biopharmaceuticals, medical devices, diagnostics, and related areas of human medicine. Launched in January of 2007, HVP III can invest in any companies in the United States but has an emphasis on opportunities in the southeastern US.
www.artuslabs.com
ArtusLabs is a technology company that enables scientific data management and workplace collaboration for research-driven entities such as biotech companies, pharmaceutical companies, and academic institutes and laboratories. Blending together the management of unstructured information and insights with social networking, personal publication, and refined data mining, ArtusLabs can significantly enhance internal and external research communication and research management. The company's "Genius" product line provides significant innovation for selecting optimal purifications, formulations, reactions, and other activities.
www.clearsidebio.com
Clearside Biomedical is an ophthalmic company specializing in the research, development and commercialization of therapeutic products through a proprietary ocular microinjection platform that targets the individual compartments of the eye. Currently, Clearside Biomedical is focused on its initial product candidate, CLS1001, under development for retinal applications through the delivery of proven therapeutics to the suprachoroidal space. Clearside Biomedical was founded by an executive team with extensive development and revenue growth expertise, focused on improving the delivery of therapeutic agents to improve standard of care for patients with sight threatening disease.
www.deviceinnovationgroup.com
Device Innovation Group ("DIG") was founded in 2011 as the result of a partnership between medical device company MDI Partners and two venture capital firms, TriStar Technology Fund and Limestone Fund. The company’s mission is to develop early stage medical devices that fulfill unmet clinical needs and underserved markets that are often overlooked by larger investment firms. DIG will incorporate a “fail fast” philosophy and a strategy of rapid advancement, welcoming new innovation from various sources including universities, hospitals and entrepreneurs.
www.clinipace.com
Clinipace is a digital clinical research organization (dCRO), providing technology-driven clinical services for phase I-IV clinical trials and registries, serving biopharmaceutical and medical device companies as well as academic medical centers. Clinipace is built on TEMPO™, an integrated EDC and Study Management platform integrating the core functional needs of clinical studies or grant management programs - Clinical Data Capture, Study Management, and Grant Tracking into a single, highly scalable, easy to use platform.
www.embrella.net
Embrella Cardiovascular, Inc., is developing an embolic protection device called the Embrella Embolic Deflector™. A large growth market exists related to percutaneous aortic valve replacement (PAVR), a relatively new procedure that involves non-surgical, catheter-based implantation of a replacement aortic valve for the treatment of aortic stenosis. During the PAVR procedure, a major complication is the increased incidence of stroke from debris dislodging from the diseased aortic valve. The Embrella device acts as a filter/deflector for these potential emboli by positioning it at the origin of the carotid arteries.
GeneCentric Diagnostics was founded in 2011 by Chuck Perou, Ph.D. and Neil Hayes, MD from The University of North Carolina at Chapel Hill, and Myla Lai-Goldman, MD. GeneCentric is focused on the development and commercialization of novel molecular diagnostic assays that enable oncologists and their patients to make more informed, individualized treatment decisions. GeneCentric brings together innovative science solving today's critical interpretive needs with experts in diagnostics and is led by Myla Goldman, MD, former chief medical and scientific officer of LabCorp.
www.histosonics.com
Histosonics is a medical device company that has developed a system for treating BPH through histotripsy, a non-invasive, image guided, robotically controlled system for precise tissue ablation. In addition to BPH treatment and prostate cancer ablation, histotripsy is applicable to many other diseases including non-invasive solid tumor ablation and thrombolysis for deep vein thrombosis.
www.pathsurg.com
Pathfinder is a medical device company dedicated to increasing the number and effectiveness of surgeries on abdominal and other soft tissue organs. Pathfinder is the first company to receive FDA clearance for a medical device to navigate liver surgery using preoperative medical images. Pathfinder's products, Explorer and Scout, improve surgical precision by allowing surgeons to "see through" the organ they are operating on by registering the surgical instrument in three-dimensional space onto pre-operative patient medical images. These products will eventually allow surgeons to perform minimally invasive abdominal procedures.
www.phasebio.com
PhaseBio is a biopharmaceutical company applying a flexible new platform for biological drugs (peptides and proteins) based on the use of elastin-like polypeptides (ELP's). PhaseBio's engineered proteins and peptides have improved manufacturing, pharmacokinetic, and pharmacodynamic properties. The company's lead programs in phenylketonuria (PKU), diabetes, and respiratory diseases are entering clinical trials.
www.spinealignmedical.com
SpineAlign is a medical device company that has developed an implantable device to treat vertebral compression fractures. The company has received a CE Mark and has completed a 50 patient study in Europe. The company's device shows the ability to restore height and reduce pain. The U.S. trial and 501(k) process is commencing.
www.tetralogicpharma.com
TetraLogic Pharmaceuticals is a biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize the activity of key Inhibitor of Apoptosis Proteins allowing pro-apoptotic signals delivered from cancer therapies and the tumor microenvironment to destroy cancer cells.
www.viamet.com
Viamet is discovering new drugs that inhibit metalloenzymes. Metalloenzymes are targeted by 10% of all currently approved drugs. Using a proprietary drug discovery platform, Viamet can design drugs with improved efficacy and safety properties. The company's lead programs in fungal disease and hormone resistant prostate cancer are at candidate selection stage.
Hatteras Venture Partners II, LP (HVP II) is a $35 million venture capital fund closed in May of 2004. HVP II involved two relationships between Hatteras and HBM Partners of Switzerland, and related entities. In the first relationship, HVP II is a $34.5 million limited partner in HBM BioCapital (USD), LP, a Cayman Island limited partnership that was invested alongside HBM BioCapital (EUR), LP from 2004 to the present (the combined fund (HBM BioCapital) has approximately $150 million under management). In the second relationship, Hatteras BioCapital, LLC, the General Partner for HVP II, is an investment advisor and part of the investment team for HBM BioCapital. Through this relationship, Hatteras and HBM worked collaboratively to develop the following portfolio of 15 clinical stage companies in the United States and Europe:
Hatteras Venture Partners I (HVP I) is a $3 million venture capital fund focused on pre-seed and seed investments in human medicine and information technology. HVP I was launched in late 2000.
www.entegrion.com
Based upon technology from UNC and East Carolina University that was funded by over a decade of Department of Navy funding, Entegrion is developing hemostatic technologies for wound management, tissue repair, and control of hemorrhage. The company's lead product (Stasilon-FR, formerly AlphaBandage) is FDA approved for use as an external hemostatic bandage.
www.noverant.com
Noverant provides web-based Learning Management Systems for Training, Compliance, and Auditing for small and medium-sized businesses. Our comprehensive, user-friendly software and services provide low-cost and company-wide solutions resulting in 100% of a company's training requirements - conforming internally and externally with any and all Regulatory Agencies.
www.respirics.com
Respirics is a respiratory drug company focused on development and delivery of powdered formulations of important respiratory medications. The company's Accu-Breathe delivery device is the first of its kind to enable the dispensing of powdered drug as the patient inhales, improving patient compliance and therapy. Respiric's lead program is Accu-30 Albuterol, the first powdered form of albuterol in clinical development in the United States.
www.phasebio.com
PhaseBio is a biopharmaceutical company applying a flexible new platform for biological drugs (peptides and proteins) based on the use of elastin-like polypeptides (ELP's). PhaseBio's engineered proteins and peptides have improved manufacturing, pharmacokinetic, and pharmacodynamic properties. The company's lead programs in phenylketonuria (PKU), diabetes, and respiratory diseases are entering clinical trials.
Synthematix (now Symyx Technologies, Inc. - SMMX) is focused on developing and deploying software solutions for discovery and medicinal chemists. In April 2005, Synthematix was acquired by Symyx Technologies.
|
